Galapagos chief executive Onno van de Stolpe said he and Gilead’s Daniel O’Day toasted their $5.1bn “transformative” research deal with a glass of champagne in New York before they unveiled it to the biopharma world in July.
The alliance was based on their co-developed filgotinib for rheumatoid arthritis, which could claim best-in-class status in the oral JAK...







